Синтез и исследование влияния низкомолекулярных отрицательно заряженных веществ на классический путь активации комплемента
Диссертация
С помощью молекулярного докинга определено, что сайт связывания дисульфатов бетулина и бисфенолов локализован на вершине глобулярного домена белка Clq между цепями, А и С рядом с положительно заряженными аминокислотными остатками LysA173, Lyscl70 и HisC167. Обнаружено, что мутантная глобулярная часть цепи С, в которой остаток LysC170 заменен на глу-тамат, не взаимодействует с ингибиторами, что… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- 1. ЛИТЕРАТУРНЫЙ ОБЗОР. ОСНОВЫ КОНСТРУИРОВАНИЯ ЛЕКАРСТВЕННЫХ СУБСТАНЦИЙ
- I. I Стратегии и подходы к созданию лекарстве) шых соединений на примере ингибиторов активации системы комплемента. /. 1 Этапы создания лекарственных препаратов
- 1. 2. Система комплемента
- 1. 3. Ингибиторы комплемента, найденные скринингом
- 1. 1. 4. Молекулярная модификация соединений-лидеров
- 1. 1. 5. Метод QSAR
- 1. 1. 6. Случайные открытия лекарственных соединений
- 1. 1. 7. ЗО-Структура белков как ююч к созданию ингибиторов комплемента
- 1. 1. 8. Ингибиторы, найденные методом фагового дисплея
- 1. 1. 9. Белковые ингибиторы системы комплемента
- 1. 3. Ингибиторы комплемента, найденные скринингом
Список литературы
- Бурделев О.О. Исследование влияния заряженных полимеров и липосом на комплемент-зависимый лизис эритроцитов. // Диссертация на соискание ученой степени кандидата химических наук. 2000. МИТХТ.
- Андия-Правдивый Ю. Э. Исследование механизма ингибирования гемолиза заряженными субстанциями. // Диссертация на соискание ученой степени кандидата химических наук. 2004. МИТХТ.
- Зефирова О.Н., Зефиров Н. С. Медицинская химия (Medicinal chemistry) II. Методологические основы создания лекарственных препаратов. // Вестн. МГУ. Сер. 2. Химия. 2000. Т.41. №.2. С.103−108.
- Fernandes Р.В. Technological advances in high-throughput screening. // Curr. Opin. Chem. Biol. 1998. V.2. P.597−603.
- Laskowski R.A., Hutchinson E.G., Michie A.D., Wallace A.C., Jones M.L., Thornton J.M. PDBsum: a Web-based database of summaries and analyses of all PDB structures. // Trends Biochem. Sci. 1997. V.22. P.488−490.
- Goodford P. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. //J. Med. Chem. 1985. V.28. P.849−857.
- Miranker A., Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. // Proteins. 1991. V. 11. P.29−34.
- DeWitte R., Shakhnovich E. SMoG: de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. // J. Am. Chem. Soc. 1996. V. l 18. P. 1 173 311 744.
- Bohacek R.S., McMartin C. Multiple highly diverse structures complementary to enzyme binding-sites results of extensive application of a de-novo design method incorporating combinatorial growth. // J. Am. Chem. Soc. 1994. V. l 16. P.5560−5571.
- Lauri G., Bartlett P. A. Caveat a program to facilitate the design of organic-molecules. // J. Comput. Aided Mol. Des. 1994. V.8. P.51−66.
- Bohm H.J. On the use of Ludi to search the Fine Chemicals Directory for ligands of proteins of known 3-dimensional structure. //J. Comput. Aided Mol. Des. 1994. V.8. P.623−632.
- Veselovsky A.V., Ivanov A.S. Strategy of computer-aided drug design. // Curr Drug Targets Infect Disord. 2003. V.3. P.33−40.
- Yu H., Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technonologies. // Drug Discov. Today. 2003. V.8. N.18. P.852−861.
- Hansch C., Leo A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. // American Chemical Society.: Washington. 1995.
- Артеменко H.B., Баскин И. И., Палюлин B.A., Зефиров Н. С. Искусственные нейронные сети и фрагментный подход в прогнозировании физико-химических свойств органических соединений. // Изв. АН, Сер. Хим. 2003. Т.1. С. 19−28.
- Rishton G.M. Nonleadlikeness and leadlikeness in biochemical screening. // Drug Discov. Today. 2003. V.8. N.2. P.86−96.
- Ройт А., Бростофф Д., Мейл Д. Иммунология (пер. с англ). // Мир.: М. 2000.
- Frank M.M. Complement in the pathophysiology of human disease. // Engl. J. Med. 1987. V.316. P. 1525−1529.
- Morgan B.P. Complement: Clinical Aspects and Relevance to Disease. // Academic Press.: Boston. 1990. P.349.
- Morgan B.P., Gasque P., Singhrao S.K., Piddlesden S.J. Role of complement in inflammation and injury in the nervous system. // Exp. Clin. Immunogenet. 1997. V.14. P.19−23.
- Asghar S.S. Membrane regulators of complement activation and their aberrant expression in disease. // Lab. Invest. 1995. V.72. P.254−271.
- Becker E.L. Synthetic inhibitors of complement in Inflammation: Mechanisms and Control (Lepow I.H. and Ward P.A. eds.).// Academic Press.: New York. 1972. pp 281−299.
- Kilgore K.S., Homeister J.W., Satoh P. S., Lucchesi B.R. Sulfhydryl compounds, captopril, and MPG inhibit complement-mediated myocardial injury. // Am. J. Physiol. 1994. V.266. N.1:2. P.28−35.
- Sim E., Gill E.W., Sim R.B. Drugs that induce systemic lupus erythematosus inhibit complement component C4. // Lancet. 1984. V.2. N^8400. P.422−424.
- Sim E., Stanley L., Gill E.W., Jones A. Metabolites of procainamide and practolol inhibit complement components C3 and C4. // Biochem. J. 1988. V.251. N.2. P.323−326.
- Harrity T.W. Goldlust M.B. Anti-complement effects of two anti-inflammotory agents, niflumic and flufenamic acids. // Biochem. Pharmacol. 1974. V.23. P.3107−3120.
- Kashyap A. Sehgal V.N., Sahu A., Saha K. Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes in vitro. // Int. J. Immunopharmacol. 1992. V.14. N.2. P.269−273.
- Mao T.S.S., Moval J.J., Pellerin P., Plescia O.J. Inactivation of hemolytic activities of serum complement by phenothiazines. // Can. J. Biochem. 1969. V.47. P.547−552.
- Sim E., Dodds A.W., Goldin A. Inhibition of the covalent binding reaction of complement component C4 by penicillamine, an anti-rheumatic agent. // U.K.Biochem. J. 1989. V.259. N.2. P.415−419.
- Makrides S.C. Therapeutic inhibition of the complement system. // Pharmacol. Rev. 1998. V.50. N.I. P.59−87.
- Grabley S., Thiericke R. eds. Drug Discovery from Nature. // Springer-Verlag. Berlin. 1999.
- Lauenstein K., Siedenstopf H.G. Fischer H. Ober die Wirkung von Heparin, Heparinoiden und Car-rageenan auf die Komponenten des Meerschweinchen Komplements in vitro. // Z. Naturforsch. 1965. V.20b. P.575−581.
- Yachnin S. Biological properties of polynucleotides. I. The anticomplementary activity of polynucleotides.//J. Clin. Invest. 1963. V.42. P.1947−1955.
- Yachnin S. Biological properties of polynucleotides. III. The anticomplementary properties of polyriboguanylic acids. //J. Immunol. 1964. V.93. P.155−156.
- Baker P.J., Osofsky S.G. Isolation and characterization of a low molecular weight inhibitor present in normal and human scrum. // Clin. Exp. Immunol. 1981. V.43. P.549−556.
- Cimanga K., De Bruyne Т., Lasure A., Van Poel В., Pieters L., Vanden Berghe D., Vlietinck A., Kambu К., Tona L. In vitro anticomplementary activity of constituents from Morinda morindoides. // J. Nat. Prod. 1995. V.58. N.3. P.372−378.
- Allan R., Rodrick M., Knobel H.R., Isliker H. Inhibition of the interaction between the complement component Clq and immune complexes. // Int. Arch. Appl. Immunol. 1979. V.58. P.140−148.
- Takada Y., Arimoto Y., Mineda H., Takada A. Inhibition of the classical and alternative pathway by aminoacids and their derivatives. // Immunology. 1978. V.34. P.509−515.
- Assefa H., Nimrod A., Walker R., Sindelar R. Synthesis and evaluation of potential complement ingibitory semisynthetic analogs of oleanolic acid. // Bioorg. Med. Chem. Lett. 1999. V 9. P. 1889−1894.
- Sahu A., Rawal N., Pangburn M.K. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. // Biochem. Pharmacol. 1999. V.57. P. 1439−1446.
- Hong K., Kinoshita Т., Miyazaki W., Izawa Т., Inoue K. An anticomplementary agent, K.-76 mono-carboxylic acid: Its site and mechanism of inhibition of the complement activation cascade. // J. Immunol. 1979. V.112. P.2418−2423.
- Packard B.D., Weiler J.M. Steroids inhibit activation of the alternative-amplification pathway of complement. // Infect. Immunol. 1983. V.40. P. 1011−1014.
- Raepple E., Hill H., Loos M. Mode of interaction of different polyanions with the first (CI), the second (C2) and the fourth (C4) component I. // Immunochemistry. 1976. V.13. P.251−255.
- Ю.Э.Андия-Правдивый, С. В. Буреева, А. П. Каплун, В. И. Швец. Получение и антигемолитическая активность дисульфатов бисфенолов и ряда дикарбоновых кислот. // Хим.-Фарм. Журнал. 2004. Т.38. № 3 С.9−12.
- Каплун А.П., Андия-Правдивый Ю.Э., Буреева С. В., Козлов JI.B., Швец В. И. Производные бетулина как ингибиторы комплемента. Патент РФ № 2 243 233. Бюллетень изобретений № 36, 27.12.2004.
- Hansch С., Yoshimoto М. Structure-activity relationship in immunochemistry. 2. Inhibition of complement by benzamidines. Hi. Med. Chem. 1974. V.17. P. l 160−1167.
- Hansch C., Yoshimoto M., Doll M. Structure-activity relationship in immunochemistry.. Inhibition of complement by benzylpyridinium ions. On the predective value of correlation equations. // J. Med. Chem. 1976. V.19. P.1089−1093.
- Burger A. A Guide to the chemical basis of drug design. // John Wiley & Sons.: New York. 1983. pp. 15−16.
- Grazer F.M.- Clemente C.D. Developing blood brain barrier to trypan blue. // Proc. Soc. Exp. Biol. Med. 1957. V.94. P.758−760.
- Nutall G.H.F., Hadwen S. // Parasitology. 1909. V.2. P.236−238.
- Mayer M., Zeiss H. //Arch. Schiffs Tropen-Hyg. 1920 V.24. P.257−261.
- Eisen, V.- Loveday, C. Effect of suramin on clotting, fibrinolysis and kinin formation. // Br. J. Pharmacol. 1973. V.49. P.678−687.
- Conrow R.B., Bauman N., Brockman J.A., Bernstein S. Synthetic mediators of complement system.
- Synthesis and biological activity of 5,5', 5″ (1,3,6-napthalene-triyl tris (sulfonylimino))-tris (l, 3-benzenedisulfonic acid) hexasodium salt. Hi. Med. Chem. 1980. V.23. P.240−242.
- Козлов JI.B. Особенности функционирования протеиназ комплемента. // Биоорган, химия. 1995. Т.20. № 3. С.229−241.
- Calcott М.А., Muller-Eberhard H.J. Clq protein of human complement. // Biochemistry. 1972. Vol.1. P. 3443−3450.
- Knobel H.R., Villiger W., Isliker H. E. Chemical analysis and electron microscopy studies of human Clq prepared by different methods. Hi. Immunol. 1975. Vol. 5. P. 78−82.
- Burton D.R., Boyd J., Brampton A.D., Easterbrook-Smith S.B., Emanuel E.J., Novotny J., Rade-maeher T.W., Van Schraven M.R., Sternberg M.J.E., Dwek, R.A. The Clq-receptor site on immunoglobulin G. // Nature (Lond.). 1980. V.288. P.338−344.
- Boackle R.J., Joknson B.J., Caughman G.B. An IgG primary sequence exposure theory for complement activation using synthetic peptides. // Nature (Lond.). 1979. V.282. P.742−743.
- Bumhouse R., Cebra J. Isotypes of IgG: Comparison of the primary structures of the three pairs of isotypes which differ in their ability to activate complement. // J. Mol. Immunol. 1979. V.16. P.907−917.
- Prystowsky M.B., Kehoe J.M., Erickson B.W. Inhibition of classical complement pathway by synthetic peptides from the second constant domain of the heavy chain of IgG. // Biochemistry. 1981. V.21. P.6349−6358.
- Anderson B.E., Fryer J.P. (1999) Method and material for inhibiting complement. U.S. Patent Number 5,977,076.
- Takada A., Shirahama S. Inhibition by various peptides of the activation of CI, the first component of complement, and the interaction of С gamma 2 domain of IgG with Clq. // Immunopharmacology. 1985. V.9. P.87−95.
- Gaboriaud C., Rossi V., Bally I., Arlaud G.L., Fontecilla-Camps J.C. Crystal structure of the catalytic domain of human complement С Is: a serine protease with a handle. // EMBO J. 2000. V.19. P.1755−1765.
- Perona J.J., Craik C.S. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. Hi. Biol. Chem. 1997. V.272. P.29 987−29 990.
- Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. // Science. 1985. V.228. P. 1315−1322.
- Kay B. K, Winter J., McCaferty J. Phage display of peptides and proteins. A laboratory manual. // Academic Press.: San Diego. 1996.
- Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library. // J. Immunol. 1996. V.157. P.884−891.
- Mastellos D., Morikis D., Isaacs S.N., Holland M.C., Strey C.W., Lambris J.D. Complement: structure, functions, evolution, and viral molecular mimiciy. // Immunol. Research. 2003. V.27. N.2−3. P.367−385.
- Nilsson В., Larsson R., Hong J., Elgue G., Nilsson Ekdahl K., Sahu A., Lambris J.D. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. // Blood. 1998. V.92. P. 1661−1667.
- Lauvrak, V., Brekke O.H., Ihle O., Lindqvist B. Identification and characterization of Clq-binding phage displayed peptides. // Biol. Chem. 1997. V.378. P.1509−1519.
- Mulligan M.S., Yeh C.G., Rudolph A.R., Ward P.A. Protective effects of soluble CRI in complement" and neutrophil-mediated tissue injury // J. Immunol. 1992. V.148. P.1479−1485.
- Levin J.L., Marsh H.C.Jr., Rudolph A.R. Principles of drug development in transplantation and autoimmunity (R.Lieberman and A. Mukherjee eds.). // R.G.Landes Company.: Texas. 1996. pp. 695−702.
- Capon D.J., Chamow S.M., Mordenti J., Marsters S.A., Gregory Т., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E., Broder S., Smith D.H. Designing CD4 immunoadhesins for AIDS therapy. // Nature. 1989. V.337. P.525−531. '
- Kalli K.R., Hsu P., Fearon D.T. Therapeutic uses of recombinant complement protein inhibitors. // Springer. Semin. Immunopathol. 1994. V.15. P.417−431.
- Greenwald R.B.- Choe Y.H., McGuire J., Conover C.D. Effective drug delivery by PEGylated drug conjugates. // Adv Drug Deliv Rev. 2003. V.55. P.217−250.
- Wang Y., Youngster S., Bausch J., Zhang R., McNemar C., Wyss D.F. Identification of the major positional isomer of PEGylated IFN alpha-2b. // Biochemistry. 2000. V.39. P. 10 634−10 640.
- Ross S.C., Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency // Medicine. 1984. V.63. P.243−273.
- Khazaeli M.B., Conry R.M., LoBuglio A.F. Human immune response to monoclonal antibodies. // J. Immunother. 1994. V.15. P.42−52.
- Mole J.E., Anderson J.K., Davison E.A., Woods D.E. Complete primary structure for the zymogen of human complement factor B. Hi. Biol. Chem. 1984. V.259. P.3407−3412.
- Buckel P. Recombinant proteins for therapy. // Trends. Pharmacol. Sci. 1996. V.17. P.450156.
- Krogsgaard-Larsen P., Liljefors Т., Madsen U. Textbook of drug design and discovery. // Taylor & Francis.: London and New York. 2002. pp.117−131.
- Hansch C., Steward A.R., Anderson S.M., Bentley D. The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics. Hi Med Chem. 1968. V. l 1. N.l. P. 1−11.
- Fujita Т., Hansch C. Analysis of the structure-activity relationship of the sulfonamide drugs using substituent constants. // J. Med. Chem. 1967. V. I0. N.6. P.991−1000.
- Box G.E.P., Hunter W.G., Hunter J.S. Statistics for experiments. // New York.: Wiley. 1978.
- Hansch C., Leo A.J. Substitution constants for correlation analysis in chemistry and biology. // New York.: Wiley. 1979.
- Donovan S.F., Pescatore M.C. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly (vinyl alcohol) high-performance liquid chromatography columns.'//J. Chromatogr. A. 2002. V.952. N. l-2. P.47−6I.
- Mannhold R., Rekker R.F., Sonntag C., ter Laak A.M., Dross K., Polymeropoulos E.E. Comparative evaluation of the predictive power of calculation procedures for molecular lipophilicity. //J. Pharm. Sci. 1995. V.84. N. l2. P.1410−1419.
- Leo A., Jow P.Y., Silipo C., Hansch C. Calculation of hydrophobic constant (log P) from pi and f constants. //J. Med. Chem. 1975. V.18. N.9. P.865−868.
- Taillandier G., Domard M., Boucherle A. Application of Verloop parameters. Comparison with other steric parameters and problems of choice of parameter. // Farmaco Sci. 1980. V.35. N.2. P.89−109.
- Yoshitomi H., Nakayama Т., Goto S. Relationship between hypoglycemic activity and binding ability with bovine serum albumin of sulfonylurea related compounds. // Yakugaku Zasshi. 1981. V.101. N. I0. P.926−931.
- Miyagawa H., Fujita T. Quantitative structure-activity study for inhibition of acetylcholinesterase by m-substituted benzyltrimethylammonium salts. // Farmaco Sci. 1982. V.37. N.12. P.797−804.
- Testa В., Seiler P. Steric and lipophobic components of the hydrophobic fragmental constant. // Arzneimittelforschung. 1981. V.31. N.7. P.1053−1058.
- Wold S. Cross-validatory estimation of the number of components in factor and principal components models. // Technometrics. 1979. V.20. P.379−405.
- Norinder U., Hogberg Г. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type. // Acta Pharm. Nord. 1992. V.4. P.73−78.
- Doweyko A.M. The hypothetical active site lattice. An approach to modelling sites from data on inhibitor molecules. //J. Med. Chem. 1988. V.31. N. 1396−1406.
- Cruciani G., Watson K.A. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. // J. Med. Chem. 1994. V.37. P.2589−2601.
- Gramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). I. Effect of shape on binding of steroids to carrier proteins. // J. Am. Chem. Soc. V. l 10. P.5959−5967.
- Kubinyi H. (ed.) 3D-QSAR in drug design. Theory, methods and applications. // Leiden: ESCOM Science Publishers. 1993.
- Jain A.N., Koile K., Chapman D. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. // J. Med. Chem. 1994. V.37. P.2315−2327.
- Norinder U. 3D-QSAR investigation of the tripos benchmark steroids and some protein-tyrosine kinase inhibitors of styrene type using the TDQ approach. // J. Chemometrics. 1996. V.10. P.533−545.
- Wilcox R.E., Tseng Т., Brusniak M.-Y.K., Ginsburg В., Pearlman R.S., Teeter M., DuRand Starr C.S., Neve K.A. CoMFA-based prediction of agonist affinities at recombinant D1 vs. D2 dopamine receptors. //J. Med. Chem. 1998. V.41. P.4385−4399.
- Klebe G., Abraham U. On the prediction of binding properties of drug molecules by comparative molecular field analysis. //J. Med. Chem. 1993. V.36. P.70−80.
- Kubinyi H (ed.) 3D-QSAR in drug design. Volume 3: resent advances. Dordrecht: Kluwer Academic Publishers. 1998.
- Bureeva S., Andia-Pravdivy J., Kaplun A. Drug design using the example of the complement system inhibitors' development. // Drug Discov. Today. 2005. V.10. N.22. P.1535−1542.
- Вейганд-Хильгетаг. Методы эксперимента в органической химии (пер. с нем.) //М.: Химия. 1968. с. 944.
- Физер Л. Физер М. Реагенты для органического синтеза (пер. с англ.). // М.: Мир. 1971. т.2. с. 157−167.
- Carvill В., Glasgow К., Roland М. Process for the synthesis of bisphenol. US Patent Number 20 081. 2004. WO 2005/5 358.
- Стилл Д. Мономеры для поликонденсации (пер. с англ.). // М.: Мир. 1976.
- Гершкович А.А., В.К.Кибирев. Химический синтез пептидов. // Наукова Думка.: Киев. 1992. с. 164.
- Джильберт Э.Е. Сульфирование органических соединений (пер. с англ.). //М.: Химия. 1969.
- Burckhardt G.N. //J. Chem. Soc. 1933. P.337.
- Демлов Э., Демлов 3. Межфазный катализ. // М.: Мир. 1987. с. 485.
- Сымон А.В. Молекулярная модификация бетулиновой кислоты как антимеланомного средства и подходы к ее солюбилизации. // Диссертация на соискание ученой степени кандидата химических наук. 2004. МИТХТ.
- Hillman A., Hillman-Elies P. Synthese des 3-Jod-L-tyrosins. //Z. Physiol. Chem. 1956. V.305. P. l 77−181.
- Habbuch I., Danho М., Zahn N. Synthese N-geschutzter cysteinsaurederivate und ihrer aktivierten ester. // Liebigs Ann. Chem. P.776−783. 1979.
- Sahu A., Pangburn M.K. Tyrosine is a potential site for covalent attachment of activated complement component C3. // Mol. Immunol. 1995. V.32. P.711 -716.
- Asghar S.S. Pharmacological manipulation of complement system. // Pharm. Reviews. 1984. V.36. N.4. P.223−244.
- Bureeva S., Andia-Pravdivy J., Bichucher A., Orishchenko D., Kaplun A. QSAR of inhibition of classical pathway of complement activation by dicarboxylic acids. // Mendeleev Commun. N.6. 2005. In press.
- Takada Y., Arimoto Y., Mineda H., Takada A. Inhibition of the classical and alternative pathways by amino asids and their derivatives. // Immunology. V. 34. P. 509−515. 1978.
- A. S. Kamat, N. F. Lewis, D. S. Pradhan. Mechanism of Ca2+ and dipicolinic acid requirement for L-alanine induced germination of Bacillus cereus BIS-59 spores. // Microbios. 1985. V.44. N.177. P.33−44.
- Gaboriaud С., Juanhuix J., Gruez A., Lacroix M. et all. The crystal structure of the globular head of complement protein Clq provides a basis for its versatile recognition properties. // J. Biol. Chem. 2003. V.278. N.47. P.46 974−46 982.
- Jle Банг Шон. Синтез бетулиновой кислоты и разработка ее липосомапьной формы. //Диссертация на соискание ученой степени кандидата химических наук. 1999. МИТХТ.
- Бояринова С.В. Молекулярная модификация бетулиновой кислоты по положению С-28. Магистерская диссертация. 2004. МИТХТ.
- Стилл Д. Мономеры для поликонденсации (пер. с англ.) // М.: Мир. 1976. с. 632.
- Catalogue of Fluka supply house 2003−2004. P.764.
- Catalogue of Fluka supply house 2003−2004. P.254.
- Козлов Л.В., Дьяков В. Л., Баталова Т. Н., Гузова В. А. Патент № 2 128 509. Бюллетень изобретений № 10. 1999.
- Agrawal A., Shrive А.К., Greenhough T.J., Volanakis J.E. Topology and structure of the Clq-binding site on C-reactive protein. //J. Immunol. 2001. V.166. P.3998−4004.